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occlusion is usually challenging, because the ma-
jority of patients remain asymptomatic [3–14].
With a growing number of pacing device and 
defibrillator implantations  [12, 15], venous ste-
nosis and, in particular, occlusion, are becoming 
a significant clinical problem. Venous obstruction 
of ipsilateral access vein impedes, or even prevents 
placement of a  lead in a patient’s body, requiring 
the use of sophisticated equipment  [3,  16]. The 
trans-venous lead extraction procedures (TLE) 
among patients with vein occlusions are more 
challenging –  apart from standard tools the sup-
plementary advanced extraction tools are often 
needed [9, 16].
Stenosis and occlusion of venous vessels with 
indwelling transvenous leads constitute one of the 
complications of permanent cardiac pacing ei-
ther by pacemaker (PM), implantable cardiovert-
er-defibrillator (ICD) or cardiac resynchroniza-
tion therapy (CRT). The unobstructed contact 
of transvenous leads with the vein endothelium 
plays a  major role in the pathophysiology of this 
phenomenon, which subsequently results in per-
manent inflammation. A  chronic inflammato-
ry process leads to venous endothelial injury, lead 
endothelialisation, narrowing of the vessel and, in 
severe cases, complete vein occlusion  [1–3]. The 
diagnosis of the incidence of venous stenosis and 
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Abstract
Background. Venous stenosis and occlusion in the presence of endocardial leads constitute one of the complica-
tions of permanent cardiac pacing either by pacemaker, implantable cardioverter-defibrillator or cardiac resyn-
chronization therapy.
Objectives. The aim of this study was to assess the incidence of stenosis and occlusions and determine the risk 
factors in patients with endocardial leads in a prospective single-center study.
Material and Methods. Two hundred eighty consecutive patients aged 25–95 years (male 68.8%) were included. 
A contrast venography examination of the ipsilateral access vein was performed. The whole study population was 
divided into 2 groups, based on the presence (group I) or absence (group II) of endocardial leads.
Results. Venous stenosis/occlusion was identified in 51 patients (37.5%) in group I and in 3 patients (3.6%) in 
group II; p < 0.0001. The lead presence most highly correlated with venous complications (OR = 4.172; p < 0.001). 
In patients with endocardial leads divided into I  A  and I  B  according to venous patency diabetes mellitus was 
proved in multivariate analysis to be the only protective factor against the development of venous stenosis/occlu-
sion (OR = 0.473; p = 0.010).
Conclusions. The presence of endocardial leads is a predisposing factor for venous stenosis/occlusion and increas-
es the risk 4-fold. The venous lesions in the presence of endocardial leads are less frequent among patients with 
diabetes mellitus (Adv Clin Exp Med 2016, 25, 1, 83–91).
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Early occurrence of access vein stenosis/oc-
clusion was examined in several prospective stud-
ies which differed in methodology and definition 
of this medical condition [4, 7, 13, 17]. Antonelli 
et al., Korkeila et al. and Da Costa et al. performed 
contrast venography and found a  narrowing of 
veins with trans-venous leads in 23% of 40, 31% 
of 150 and 64% of 202 patients, respectively, in the 
examined cohort [4, 7, 17]. Van Roden et al. con-
firmed the diagnosis of venous obstruction dur-
ing the first post-implantation year with Doppler 
ultrasound in 23% of a  population consisting of 
145  patients with PM or ICD  [13]. In previously 
mentioned studies, 2% to 6% of patients exhibited 
clinical symptoms of venous obstruction [4, 7, 13].
According to retrospective studies, in which 
a  total number of 727 patients prior to follow-up 
PM or ICD procedure were evaluated mainly by 
contrast venography, the incidence of venous ste-
nosis was established between 23% and 33% [3, 5, 
8–10, 16]. Furthermore, Zuber et  al., utilizing 
Doppler ultrasound, demonstrated stenosis/occlu-
sion of veins in 57% of patients after a  mean of 
41 months post PM/ICD implantation [14].
The discrepancies in reported incidence of ve-
nous obstruction may be explained by different 
baseline characteristics of study populations, diag-
nostic methods (contrast venography vs. Doppler 
ultrasound) and various lead dwell time in cardio-
vascular system.
The association between lead dwell time and 
the incidence of venous stenosis/occlusion as-
sessed by Doppler US was prospectively studied by 
Roden et al. who demonstrated a lower incidence 
of venous complications in the first post-implan-
tation year compared with Zuber et al., who retro-
spectively determined the incidence after a  mean 
follow-up of 41  months after PM/ICD implanta-
tion [9, 13].
Regarding the definition of venous stenosis 
and occlusion, it depended on the type of a  di-
agnostic method. When Doppler ultrasound was 
used  [13, 14], the diagnosis was based on visual-
izations of thrombotic masses, an abnormal com-
pression ultrasonography result and monophasic 
venous flow. Additionally, Doppler ultrasound did 
not provide information on the presence of collat-
eral circulation, which in turn facilitates contrast 
venography  [13]. In venography-based studies 
the classification of venous stenosis degree dif-
fered substantially among authors [3–5, 7–11, 16]. 
Antonelli et  al. stratified stenosis as partial and 
complete and did not perform the assessment of 
incomplete occlusion grade and collateral circula-
tion [4]. Da Costa et al. evaluated the grade of ve-
nous stenosis according to the percentage of intra-
luminal contrast filling defect, classifying it as mild 
(up to 20%), moderate (21–69%), severe (70–99%) 
and occlusion (100%). Collateral circulation de-
gree was classified according to the number and 
flow of the new vessels in mild (one vessel and 
lower flow), moderate (two vessels and moderate 
flow), and important (three or more vessels and an 
adequate flow) [7].
The risk factors for venous stenosis/occlusion 
development were presented in several studies and 
include multiple leads, dual-coil ICD leads, infec-
tion, left ventricle ejection fraction under 40%, his-
tory of previous venous thrombosis and female hor-
mone use  [3, 5, 7, 9, 13, 16]. Use of antiplatelet/ 
/anticoagulant drugs had preventive effect on venous 
lesions [3, 9, 13, 16]. The predisposing factors lead-
ing to venous abnormalities are not fully understood.
To address the issue of risk factors and deter-
mine the incidence of stenosis and occlusions in 
patients with endocardial leads, we designed a pro-
spective single-center study.
Material and Methods
Two hundred eighteen consecutive patients 
were admitted to hospital for their cardiac im-
plantable electronic device (CIED) implantation, 
device upgrade, generator replacement or trans-
venous lead extraction. Patients who had under-
gone TLE procedure in the past and patients who 
were referred with infectious indications for TLE 
were excluded from the analysis. Prior to the op-
eration, a contrast venography examination of the 
ipsilateral access vein was performed. The study 
was approved by the Ethics Committee. The study 
inclusion criteria included the absence of contra-
indications to venography and written consent ob-
tained from the patient.
Performance and Assessment 
of Venography
In the operating room, 10 to 20  mL of high 
quality contrast medium Iomeron 350 (350  g  io-
dine/mL) was injected through the peripheral arm 
vein on the side which was to be studied. Con-
trast medium flow in the cephalic, axillary, subcla-
vian and brachiocephalic veins, as well as the su-
perior vena cava, was observed and recorded by 
cineangiography.
The narrowing of the vessel was identified and 
graded in the percentage of obstructed vein lumen 
in the presence of venous contrast filling defect, 
filmed in frontal (PA) projection. A positive result 
of venography (significant abnormality in venous 
patency) was defined as a  total venous occlusion 
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(Fig.  1) or visible stenosis with collateral circula-
tion on venogram (Fig. 2).
Furthermore, all the patients filled out the 
questionnaire regarding the clinical symptoms of 
obstruction in upper body venous flow, such as 
superficial venous collaterals on the chest, skin 
color changes, paresthesia and swelling of ipsi-
lateral upper extremity, neck and face and anus 
hemorrhoids.
We determined the incidence of venography-
based significant venous obstructions, the clinical 
symptoms and predictive factors.
The following clinical and demographic pa-
rameters were evaluated as potential risk factors for 
vein-related complications: age, sex, antiplatelet/ 
/anticoagulant drugs, statins, comorbidities and 
selected blood tests:
– white blood cells count (WBC) [×1000/mL]),
– diabetes mellitus,
– chronic obstructive pulmonary disease 
(COPD),
– nicotinism,
– history of venous thrombosis,
– paroxysmal or permanent supraventricular 
tachyarrhythmia: atrial flutter/fibrillation (AT/AF)
– heart failure defined as left ventricle ejection 
fraction ≤ 40%,
– chronic kidney disease defined as an in-
crease in serum creatinine over 1.2 mg/dL or esti-
mated glomerular filtration rate (eGFR) by CKD- 
-EPI formula less than 60 mL/min/1.73 m2,
– the presence of cardiac implants other than 
endocardial leads,
– history of surgical procedures and inju-
ries in the area of neck and chest (strumectomy, 
sternotomy),
– only in patients qualified for elective trans-
venous lead extraction and in patients with heart 
failure: C-reactive protein (CRP), N-terminal pro-
hormone of brain natriuretic peptide (NT-pro-
BNP) and D-dimer tests,
– additional type of PM/ICD lead insulation.
The whole study population was divided in-
to two groups, based on the presence or absence 
of endocardial leads in the cardiovascular sys-
tem. Group I  consisted of 136  patients with im-
planted endocardial leads (68.8% men), average 
age 68.0 ± 12.1 years, qualified for following pro-
cedures: 1)  generator change (33 pts –  24.3%), 
25 pts first reimplantation, 8 pts second and con-
secutive reimplantation; 2) device upgrade (22 pts 
–  16.1%), 17 pts upgrade of single lead device 
(PM – 4, ICD – 6) and 5 patients upgrade of du-
al-chamber devices (PM – 4, ICD – 1); 3) transve-
nous lead extraction (81 – 59.6%).
Group II (control) consisted of 82  patients 
(56 male), average age 73.1 years and before first 
implantations: PM – 63 pts, ICD 16 pts, CRT 3 pts.
The prevalence of potential risk factors men-
tioned above was compared in both groups.
The group with implanted leads was then di-
vided into subgroup I A – with substantial abnor-
malities in venous blood flow, and I B – with cor-
rect blood flow. In these two subgroups (I A and 
I  B) we performed an analysis of demograph-
ic factors, comorbidities and risk factors for ve-
nous stenosis/occlusion with regard to the lead 
number and type, lead insulation type, lead 
dwell time in cardiovascular system, presence 
of abandoned/non-functional and/or fractured, 
dropped-in leads forming loops in the heart and 
blood vessels.
Fig. 1. Complete obstruction of the left subclavian 
vein. A well-developed collateral circulation bypassing 
the site of obstruction
Fig. 2. A significant stenosis of left subclavian vein (A) 





The data was evaluated using STATISTICA 10 
by StatSoft. Quantitative variables are presented as 
a mean with standard deviations. Categorical vari-
ables are presented as an exact number and per-
centage of the whole analyzed group. Normality of 
continuous variables was evaluated using Shapiro-
-Wilk test. Differences between two groups were 
tested by Mann-Whitney U-test. The comparisons 
of categorical variables (frequency tables) were an-
alyzed using χ2 independence test. Two-way tables 
were assessed with the χ2 test with Yates correction 
or Fisher exact test. Univariate and multiple logis-
tic regression analyses were used to determine fac-
tors that were associated with risk of venous occlu-
sion. A p-value < 0.05 was considered significant.
Results
None of the 218 patients aged 25 to 95 years 
(average 70.2 years) exhibited any adverse reaction 
to contrast dye. Group I (patients with already im-
planted leads) was larger than group II (before first 
implantation) – 62.4% of the study cohort. The risk 
factors and venogram results for the whole popula-
tion are listed in Table 1.
Female patients were in the minority (31.2%). 
Among the underlying disease conditions the 
most common were supraventricular arrhythmias 
(43.1%) and heart failure (34.4%). A  large per-
centage of patients used statins (46.8%) and anti-
platelet/anticoagulation drugs (40.4%). Abnormal 
venograms were detected after the examination of 
54 patients (24.8%). The patients with endocardi-
al leads (group I) were compared with the patients 
from the control-group (group II), regarding the 
incidence of venous complications and the risk 
factors. The results are presented in Table 2.
The narrowing was identified in 51  patients 
(37.5%) in group I  and in 3  patients (3.6%) in 
group II; p < 0.0001. One patient with a total oc-
clusion of the left brachiovephalic vein after car-
diac sugery, 2 patients with anatomical variability. 
These two groups did differ significantly in terms 
of demographic factors and the presence of comor-
bidities. The patients in group II were significantly 
older and presented worse kidney function. On the 
other hand, patients with heart failure and left ven-
tricular ejection fraction ≤ 40% were significantly 
more prevalent in group I, which is somehow re-
flected by a higher portion of ICD/CRT patients in 
group I  –  26.9% vs. 22% in group II. In univar-
iate analysis conducted for the whole study co-
hort, the only statistically significant factor which 
predisposed to substantial venous stenosis was 
the presence of endocardial leads (OR  =  3.975; 
p < 0.001). Multivariate analysis confirmed the pre-
disposing role of endocardial leads (OR  =  4.172; 
p < 0.001). The lead presence most highly correlat-
ed with venous complications and was associated 
with approximately four-fold (OR = 4.2) increased 
risk (Table 3).
We compared patients with endocardial leads 
divided into I A and I B according to venous paten-
cy. The findings are presented in Table 4. Diabetes 
Table 1. The risk factors and venograms results for study 
population
Number of pts 218
Female gender 68 (31.2)
Use of statins 102 (46.8)
AT/AF 94 (43.1)
Anticoagulation treatment 88 (40.4)









Chronic kidney disease (eGFR less 
than 60 mL/min/1.73 m2)
12 (5.5)
The presence of cardiovascular 
implant (excluding PM/ICD leads)
7/200* (3.5)
History of thrombosis 7 (3.2)
Use of hormone replacement ther-
apy (among women)
1/68* (1.5)
WBC (×1000/μL) 215* 6.7 ± 1.9
Creatinine (mmol/L) 214* 93.8 ± 47.8
eGFR – CKD-EPI formula  
(mL/min/1.73 m2) 
214* 69.1 ± 17.3
CRP (mg/L) 93* 12.5 ± 41.6
NT-pro BNP (pg/mL) 87* 1844 ± 4880
D-dimer (µg/L) 81* 769 ± 1073
Presence of stenosis/occlusion 54 (24.8)
* number of patients countable in the analysis.
Data are presented as mean ± standard deviation or num-
ber (percentage). AF – atrial fibrillation, AT – atrial tachy-
cardia, COPD – chronic obstructive pulmonary disease, 
CRP – C reactive protein, eGFR – estimated glomerular 
filtration rate, NT-pro BNP – N-terminal prohormone of 
brain natriuretic peptide, WBC – white blood cells count.
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mellitus was significantly more frequent in pa-
tients without venous complications – group I B; 
p = 0.01. Furthermore, univariate analysis revealed 
that the diabetes mellitus was the only protective 
factor against the development of venous lesions in 
patients with CIED (PM, ICD, CRT) (OR = 0.479; 
p  =  0.01). In multivariate analysis diabetes mel-
litus was proved to be independently associated 
with lower risk of venous stenosis (OR  =  0.473; 
p = 0.01) (Table 5).
Regarding the clinical symptoms of venous 
obstruction in group I, 6 patients (4.4%) had visi-
ble superficial cutaneous collateral veins on chest, 
3  patients exhibited the skin color changes, par-
esthesia and/or swelling of the upper extremity. 
None of the patients experienced swelling of the 
head.
Discussion
Considering the occurrence of venous ste-
nosis/occlusion in the presence of endocardi-
al leads we must take into consideration the uti-
lized venous visualization method, the definition 
of venous stenosis/occlusion and the lead dwell-
ing time.
The assessment of vein patency among patients 
with endocardial lead and controls was performed 
by contrast venography, which is considered the 
gold standard [6]; however, there exist other meth-
ods such as venous Doppler ultrasound  [13, 14] 
and isotope studies [18].
In the present study venous occlusion and ste-
nosis was detected in 37.5% of patients with in-
dwelling endocardial leads. The previous studies 
reported lower incidence of the complication ex-
cept for two authors who identified venous occlu-
sion and stenosis in higher percentage of patients 
Table 2. Comparison of the risk factors and venous complications incidence between group I and group II
Parameter Presence of PM/ICD 
leads [Group I]
Initial PM/ICD  
implantation [Group II] 
p-value
No. of patients 136 82 –
Age (years) 68.0 ± 12.1 73.8 ± 9.6 < 0.001
Female gender 42 (30.2) 26/82 (31.7) 0.8986
Chronic kidney disease (eGFR< 60 mL/min/1.73 m2) 5/132* (3.8) 7/82 (8.5) 0.2234
Diabetes 27 (19.8) 14/82 (17.1) 0.6109
History of sternotomy 20 (14.7) 13/82 (15.8) 0.8188
History of strumectomy 1 (0.7) 2/82 (2.4) 0.5580
Tabacco 19 (14.0) 16/82 (19.5) 0.2803
COPD 13 (9.6) 4/82 (4.9) 0.3232
AT/AF 55 (40.4) 39/82 (47.6) 0.3038
History of thrombosis 3 (2.2) 4/82 (4.9) 0.2419
LVEF ≤ 40% 54 (39.7) 21/82 (25.6) 0.0338
Use of statins 62 (45.6) 40/82 (48.8) 0.6473
Anticoagulation treatment 56 (41.2) 32/82 (39.0) 0.7537
Use of hormone replacement therapy (among women) 1/42* (0.7) 0/26* (0.0) 1.0000
WBC (×1000/μL) 133* 6.6 ± 1.9 6.8 ± 1.8 0.2654
Creatinine (mmol/L) 132* 93.5 ± 58.1 94.4 ± 23.2 0.0883
eGFR – CKD-EPI formula (mL/min/1.73 m2) 132* 71.8 ± 18.1 64.9 ± 15.1 0.0026
Presence of stenosis/occlusion 51/136 (37.5) 3/82 (3.7) < 0.0001
Data are expressed as mean ± standard deviation or number (percentage); p-value < 0.05 was considered significant.
* number of patients countable in the analysis. AF – atrial fibrillation, AT – atrial tachycardia, COPD – chronic obstruc-
tive pulmonary disease, eGFR – estimated glomerular filtration rate, LVEF – left ventricular ejection fraction, WBC – white 
blood cells count.
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– 57% and 64% [7, 14]. The substantial differences 
among authors depend more on the criteria which 
were used to define venous stenosis/occlusion in 
the presence of endocardial leads rather than the 
lead dwell time or method of venous visualisation.
We defined a simple criterion of venous com-
plication, which is complete occlusion or an ob-
vious narrowing with collateral vein development. 
Da Costa et  al.  [7] considered any change in the 
contour of venous vessel with endocardial leads as 
a venous stenosis and revealed the high rate of ve-
nous stenosis/occlusion (64%) after much short-
er mean lead dwell time (6 months). In other ve-
nography-based studies the changes in veins with 
or without the presence of collateral circulation 
were detected in 23–33% of patients regardless the 
length of lead dwell time  [3–5, 8, 10, 13, 16, 17]. 
Only three discussed studies presented compa-
rably long lead dwell time of 72  months and the 
rate of abnormal contrast flow reached 25%, 23% 
and 26% respectively [5, 8, 9]. In study by Bracke 
et  al. and Goto et  al. the detailed criteria of VSO 
were not specified. Li et al. found the total venous 
occlusion in 26% of patients in a population which 
was comparable to our patient population with re-
spect to mean lead dwell time and sample size. Ac-
cording to Li et al., total venous occlusion was ob-
served in 11% of patients without device related 
infections and in 32% of patients referred to TLE 
due to infectious indications [9].
In our study clinical manifestation of signs or 
symptoms of venous obstruction were present in 
6 patients (4.4%), which correlates with data from 
the literature (2–6%) [4, 7, 13, 14]. It is reasonable 
to assume that the symptoms related to venous ste-
nosis/occlusion correlate negatively with collateral 
circulation degree [7].
The analysis of the control group revealed the 
rates of venous stenosis/occlusion (3.6% vs. 37.5% 
in group I). The venous anomalies in the control-
group were infrequent and related to intersubject 
variations of the anatomy. Due to the determina-
tion of venous stenosis/occlusion in the control co-
hort we demonstrated that indwelling leads facili-
tate the development of venous obstruction. It is 
noteworthy that there have been no randomized 
Table 3. Univariate and multivariate analysis of risk factors of venous complications in the whole study population
Parameter Univariate analysis Multivariate analysis
OR 95% CI p-value OR 95% CI p-value
Age (years) 0.982 0.957–1.008 0.182
Female gender 1.129 0.815–1.563 0.466
Presence of PM/ICD 3.975 2.177–7.257 < 0.001 4.172 2.276–7.648 < 0.001
History of sternotomy 1.017 0.660–1.566 0.939
History of strumectomy 0.809 0.241–2.713 0.731
Tabaco 1.176 0.753–1.837 0.477
COPD 1.260 0.662–2.397 0.482
AT/AF 0.846 0.617–1.160 0.299
LVEF ≤ 40% 1.139 0.828–1.565 0.424
Use of statins 1.177 0.862–1.607 0.305
Anticoagulation treatment 0.865 0.628–1.190 0.372
History of neoplasm 0.952 0.490–1.849 0.884
WBC (× 1000/μL) 0.972 0.823–1.147 0.737
Creatinine (mmol/L) 0.997 0.988–1.007 0.575
eGFR – CKD-EPI formula 
(mL/min/1.73 m2)
1.007 0.989–1.025 0.475
NYHA class III, IV 0.801 0.491–1.307 0.375
Univariate and multiple logistic regression analyses. P-value < 0.05 was considered significant; OR – odds ratio, CI – confi-
dence interval; AF – atrial fibrillation, AT – atrial tachycardia, COPD – chronic obstructive pulmonary disease, eGFR – esti-
mated glomerular filtration rate, ICD – implantable cardioverter defibrillator, LVEF – left ventricular ejection fraction, 
PM – pacemaker, WBC – white blood cells count.
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controlled trials assessing the venous complica-
tions in CIED recipients.
In the group of patients with endocardial 
leads, diabetes mellitus was proved to be a  pro-
tective factor against the development of venous 
stenosis (OR = 0.47). Such an observation has not 
been reported in the literature yet. Implantation of 
devices or biomaterials triggers a series of host re-
actions at the injury site that include interactions 
material/tissue, provisional matrix formation, 
acute and chronic inflammation, granulation tis-
sue development, foreign body reaction, and fi-
brosis and fibrous capsule development. Much 
of the knowledge on this adverse healing follow-
ing foreign body material implantation has come 
from normoglycemic individuals. An adverse for-
eign body reaction that invariably occurs adjacent 
to implant devices is poorly characterized in the 
Table 4. Comparison of patients with endocardial leads divided into group IA and IB according to venous patency
No. of patients 51 85 –
Age (years) 68.9 ± 14.0 67.5 ± 10.9 0.3993
Female gender 19 (37.2) 23 (27.1) 0.2918
Number of leads (1) 1.63 ± 0.56 1.59 ± 0.66 0.5112
Lead dwell time (months) 98.0 ± 68.5 108.4 ± 76.0 0.4902
Diabetes 4 (7.8) 23 (27.1) 0.0125
Chronic kidney disease (eGFR less than 60 mL/min/1.73 m2) 2 (3.9) 3 (3.5) 1.0000
History of sternotomy 6 (11.8) 14 (16.5) 0.6170
History of strumectomy 1 (2.0) 0 (0.0) 0.3750
Tabacco 7 (13.7) 12 (14.1) 0.8481
COPD 3 (5.9) 10 (11.8) 0.4075
AT/AF 20 (39.2) 35 (41.2) 0.8215
History of thrombosis 0 (0) 3 (3.5) 0.2917
LVEF ≤ 40% 18 (35.3) 36 (42.3) 0.4154
Use of statins 20 (39.2) 42 (49.4) 0.2478
Anticoagulation treatment 19 (37.2) 37 (43.5) 0.4717
Use of hormone replacement therapy (among women) 0/19* (0) 1/23* (4.3) 1.0000
WBC (×1000/μL) 50* 6.7 ± 1.7 83* 6.6 ± 2.0 0.7136
Creatinine (mmol/L) 50* 91.3 ± 24.1 82* 94.8 ± 71.5 0.4786
eGFR – CKD-EPI formula (mL/min/1.73 m2) 50* 69.6 ± 16.6 82* 73.2 ± 18.9 0.2279
CRP (mg/L) 32* 15.6 ± 67.3 49* 7.9 ± 13.8 0.1531
D-dimer (µg/L) 30* 667 ± 759 48* 740 ± 1152 0.9713
NT-pro BNP (pg/mL) 32* 1161 ± 1147 48* 2379 ± 6469 0.5264
Lead insulation:
  silicone insulation
  polyurethane insulation
  silicone and polyurethane insulation
  silicone and Optim insulation
  polyurethane and optim insulation 



















Data are presented as mean ± standard deviation or number (percentage); p-value < 0.05 was considered significant; * num-
ber of patients countable in the analysis; AF – atrial fibrillation;AT – atrial tachycardia; COPD – chronic obstructive pul-
monary disease; eGFR – estimated glomerular filtration rate; HDL – high-density lipoprotein; ICD – implantable cardioverter 
defibrillator; LDL – low-density lipoprotein; LVEF – left ventricular ejection fraction; NT-pro BNP – N-terminal prohormone 
of brain natriuretic peptide; PM – pacemaker; TCH – total cholesterol; TG – total glyceride; WBC – white blood cells count.
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diabetic environment. There is evidence that hy-
perglycemia compromises all major components 
of the innate immune system, including phagocy-
tosis, opsonization, glycosylation, and inactivation 
of circulating immunoglobulins. In consequence, 
diabetes affects the cellular response to tissue inju-
ry and delays wound healing. In a study conduct-
ed on rats it was observed that fibrous formation 
and presence of foreign body giant cells, the typical 
features of the foreign body reaction, were attenu-
ated in the hyperglycemic environment  [19]. We 
assume that these effects may contribute to a de-
creased risk of venous stenosis in patients with in-
dwelling endocardial leads. Undoubtedly, this phe-
nomenon requires further investigation [20].
We did not confirm previously reported risk 
factors, such as the number and type of leads, lead 
insulation usage of temporary pacing lead, heart 
failure with left ventricle ejection fraction below 
40%, female hormone use, history of previous ve-
nous thrombosis [3, 7, 13, 16]. Our experience has 
shown no effect of antiplatelet/anticoagulation 
drugs on venous stenosis/occlusion in presence 
of endocardial leads in opposition to Van Roden 
et al. and Haghjoo et al. [13, 16].
Study Limitations
The presented study is single-center and non-
randomized. Its limitation is the narrow size of the 
assessed population. Nevertheless, previous stud-
ies on venous occlusion/stenosis in the presence of 
endocardial leads were conducted in a  compara-
ble number of patients and without control group. 
A considerable percentage of patients were referred 
to TLE procedures. This fact results from the spe-
cialization of our center, which is the treatment of 
electrotherapy complications. Patients who under-
went TLE procedure in the past or were referred 
for TLE due to infectious reasons were excluded 
from the study because still little is known about 
the influence of TLE procedures and infections on 
the late venous stenosis/occlusion formation.
The authors have concluded that the presence 
of indwelling endocardial leads is a  predisposing 
factor for venous stenosis/occlusion and increas-
es the risk 4-fold. Among patients with endocardi-
al leads, diabetic patients develop venous stenoses 
significantly less frequently.
Table 5. Univariate and multivariate analysis of risk factor of significant vein occlusion in group I – patients with presence 
of PM/ICD leads
Parameter Univariate analysis Multivariate analysis
OR 95% CI p-value OR 95% CI p-value
Age (years) 1.010 0.980–1.039 0.263
Female gender 1.265 0.873–1.834 0.214
Diabetes 0.479 0.273–0.842 0.010 0.473 0.268–0.835 0.010
Number of leads (1) 1.106 0.634–1.930 0.722
Lead dwell time (months) 0.998 0.993–1.003 0.427
No. of PM/ICD/CRT replacement (1) 1.207 0.732–1.992 0.461
AT/AF 1.042 0.731–1.485 0.395
LVEF ≤ 40% 1.161 0.811–1.661 0.416
WBC (×1000/μL) 1.012 0.843–1.214 0.900
Creatinine (mmol/L) 0.999 0.992–1.006 0.741
GFR – CKD-EPI formula  
(mL/min/1.73 m2)
0.989 0.970–1.009 0.272
Anticoagulation treatment 1.139 0.798–1.626 0.486
NYHA class III, IV 0.599 0.348–1.032 0.065 0.586 0.334–1.026 0.061
Univariate and multiple logistic regression analyses. P-value < 0.05 was considered significant.
OR – odds ratio; CI – confidence interval; AF – atrial fibrillation; AT – atrial tachycardia; ICD – implantable cardioverter 
defibrillator; LVEF – left ventricular ejection fraction; PM – pacemaker.
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